DELTICOM-AG/YOURTYRES
29.9.2016 14:00:50 CEST | Business Wire | Press release
Just in time for the start of the winter season, Yourtyres.co.uk is extending its online shop to include yet more convenient features. For tyre dealers and workshops, this means that purchasing tyres in the online B2B shop provided by Delticom, Europe’s largest online tyre dealer, will be even easier and quicker than before.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160929005678/en/
In future, the following options will aid dealer partners of Yourtyres.co.uk to find the right tyres:
Even more convenient tyre search based on car model:
You can now search via match code, tyre number or via car model, a totally new search option. The search results display at a glance which tyres are approved for the customer’s car.
Bonus for car dealerships:
Especially for car dealerships, at Yourtyres.co.uk searching for original equipment (OE) is now possible as well as searching via the respective car model.
Customer reviews with tyre details:
This is also a new feature: From now on, all customer reviews from tyre testing platform Tyretest.com will be displayed on the relevant product pages at Yourtyres.co.uk . Dealer partners of Yourtyres.co.uk will thus have access to countless opinions and tips when selecting tyres and advising customers. At Tyretest.com , customers review many tyres that don’t make it to the major magazines. Even cheap tyres often perform well here, as the price-performance ratio is good and the overall result is therefore positive.
“We see ourselves as partners to our dealer customers. That’s why, on top of offering good prices, we want the new shopping functions to make shopping on Yourtyres.co.uk as simple and convenient for them as possible”, explains Thorsten Orbach, Head of Merchant Business at Delticom B2B and Yourtyres.co.uk . “For many commercial customers, one thing is particularly important: flexibility. Thanks to our large product range and our in-house warehouse stock, our partners can provide products at short notice for all their customer groups and vehicles. We offer speedy delivery and fantastic flexibility. There are no minimum order quantities or ordering fees, and we offer a variety of payment methods and return options.”
“In addition to the shop’s many convenient functions and countless shopping benefits for dealers, our new Delticom B2B services offer great potential for attracting new customers and additional business”, expands Andreas Faulstich, Head of B2B at Delticom AG, the partnership trading model. “The ability to co-operate as a fitting partner enables workshops to expand their business to include customers who buy their tyres in B2C shops such as Mytyres.co.uk .”
About Yourtyres.co.uk
Yourtyres.co.uk is an exclusive British online store from Delticom AG for workshops, retailers, wholesalers, tyre fitters/service stations and car accessories. With over 15 years of expertise in the online tyre business, the specialist B2B team of www.yourtyres.co.uk offers its customers a spectacular range of car and motorbike tyres of all brands and dimensions for all types of vehicles, tyres for light trucks, trucks and buses, custom tyres, complete wheel sets, car spare parts and accessories, engine oil and batteries. In addition to favourable purchasing conditions, retail customers benefit from the online shop’s time-saving tyre search function, high availability, reliable delivery thanks to in-house warehouses as well as a simple registration process with no hidden costs - from the very first tyre.
Online shop for dealers and workshops in the UK: www.yourtyres.co.uk and 26 other countries.
Information about the company : www.delti.com
Tyre tests : www.tyretest.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160929005678/en/
Contact:
Press contact:
insignis Agentur für
Kommunikation GmbH
(GPRA)
Henning Jahns
Tel.: +49-511-132214-14
Fax:
+49-511-132214-99
delticom@insignis.de
or
Delticom
AG
Anne Lena Peters
Tel.: +49-511-93634-8909
Fax:
+49-511-93634-8301
anne.lena.peters@delti.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom